纳武利尤单抗治疗中患者18F-FDG PET/CT上COVID-19肺炎模仿免疫治疗诱导性肺炎
本文报道一名51岁转移性肾细胞癌男性患者在纳武利尤单抗治疗期间发生SARS-CoV-2感染,其18F-FDG PET/CT表现模仿免疫治疗诱导性肺炎。文章指出肿瘤患者早期识别COVID-19对快速隔离、避免院内传播至关重要,但在免疫治疗患者中早期诊断具有挑战性,因为药物性肺炎可呈现相似的临床和影像学特征。
要点
- 免疫治疗患者中COVID-19肺炎与药物性肺炎临床和影像学特征相似,早期鉴别困难。
- 肿瘤患者早期识别COVID-19对快速隔离和避免院内传播至关重要。
- 本文报道一例51岁转移性肾细胞癌患者纳武利尤单抗治疗期间SARS-CoV-2感染的PET/CT表现。
核心结论
- 在纳武利尤单抗治疗的转移性肾细胞癌患者中,SARS-CoV-2感染的18F-FDG PET/CT表现可模仿免疫治疗诱导性肺炎。
研究设计与样本
- 本文为病例报告,描述一名51岁转移性肾细胞癌男性患者在纳武利尤单抗治疗期间发生SARS-CoV-2感染的18F-FDG PET/CT表现。
主要发现
- 文章指出肿瘤患者早期识别COVID-19对快速采取隔离措施和避免院内传播至关重要。
- 文章指出在免疫治疗患者中早期诊断可能具有挑战性,因为药物性肺炎可呈现相似的临床和影像学特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Within a few months, coronavirus disease 2019 (COVID-19) has become a pandemic with more than 2 million patients infected and a high mortality rate. Early detection of COVID-19 in oncologic patients is crucial in order to rapidly apply isolation measures and avoid nosocomial spread. However, early diagnosis may be challenging, especially in cancer patients under treatment with immunotherapy as drug-induced pneumonitis can present similar clinical and radiological features. We describe the findings of a SARS-CoV-2 infection on PET/CT with F-FDG in a 51-year-old man with metastatic renal cell carcinoma under treatment with nivolumab.
引用
- Artigas C, Lemort M, Mestrez F, et al. COVID-19 Pneumonia Mimicking Immunotherapy-Induced Pneumonitis on 18F-FDG PET/CT in a Patient Under Treatment With Nivolumab. Clin Nucl Med. 2020. PMID: 32520508. doi:10.1097/RLU.0000000000003152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。